

Vector pLNCX2

Catalog No. NR-2819

For research use only. Not for human use.

Contributor:

Ellis L. Reinherz, M.D., Professor of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts

Manufacturer:

NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH

Product Description:

The Clontech Laboratories vector pLNCX2 is a plasmid designed for retroviral gene delivery and expression. It is similar to the pLNCX plasmid,¹ but is slightly smaller and contains a more versatile multiple cloning site. pLNCX2 is suitable for use as a control in studies with HLA allele expression plasmids available from BEI Resources (NR-2776 to NR-2818).² The plasmid was produced in *Escherichia coli* DH5 α TM-T1^R cells (InvitrogenTM) and extracted using a QIAGEN[®] EndoFree[®] Plasmid Maxi Kit.

Vector: pLNCX2

Selection: Ampicillin (Prokaryotic)/G418 (Eukaryotic)

Note: The pLNCX2 vector has not been completely sequenced. A sequence compiled from information in the published literature, sequence databases, and other sources is available from Clontech Laboratories.

NR-2819 has been qualified for use in bacterial transformations.

Material Provided:

Each vial contains 20 to 50 ng of plasmid DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0). The concentration is shown on the Certificate of Analysis. The vial should be centrifuged prior to opening.

Packaging/Storage:

NR-2819 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read “The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Vector pLNCX2, NR-2819.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following

publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC[®] nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC[®] nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC[®] and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Miller, A. D., and Rosman, G. J. “Improved Retroviral Vectors for Gene Transfer and Expression.” Biotechniques 7 (1989): 980-982, 984-986, 989-980. PubMed: 2631796.
2. Reche P. A., et al. “Elicitation from Virus-Naive Individuals of Cytotoxic T Lymphocytes Directed Against Conserved HIV-1 Epitopes.” Med. Immunol. 5 (2006): 1-14. PubMed: 16674822

ATCC[®] is a trademark of the American Type Culture Collection.

